Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Takeda to reclaim sales rights to Actos from Lilly
According to the paper, the Japanese drugmaker intends to sell the diabetes drug in these places by itself. The company plans to start selling Actos in Canada in
According to the paper, the Japanese drugmaker intends to sell the diabetes drug in these places by itself. The company plans to start selling Actos in Canada in
According to the news source, most of the job cuts are likely to involve sales personnel. The reduction also involves attrition and hiring freezes. Loss of patent protection,
For the fourth quarter of 2008, sales were $12.4 million, compared to $9.2 million for the fourth quarter of 2007. For the 12 months ended December 31, 2008,
The net income in the first quarter of fiscal 2009 is primarily the result of a 23% decrease in marketing, general and administrative expenses and a 23% decrease
The company has reported net sales of $5.07 million for the first quarter of 2009 compared to $5.76 million for the same period of 2008. Michael Perry, CEO
Kanan brings two decades of financial experience to Sigma-Aldrich. His most recent position at ArvinMeritor was vice president finance-light vehicle systems since 2006. His prior experience at ArvinMeritor
NovaBay Pharmaceuticals, a clinical stage biopharmaceutical company, has reported a net loss of $1.5m, or $0.07 per share, for the fourth quarter of 2008, compared to a net
Bioniche Life Sciences, a research-based biopharmaceutical company, has completed recruitment in its initial Phase III registration trial evaluating Urocidin in the treatment of non-muscle-invasive bladder cancer that is
Wyeth Pharmaceuticals, a division of Wyeth, has submitted a biologic license application to the FDA for Prevnar 13, pneumococcal 13-valent conjugate vaccine. The Prevnar 13 submission to the
ReNeuron Group, a UK-based stem cell company, has reported positive preclinical efficacy data with its lead CTX stem cell line in a model of peripheral arterial disease, a